Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patientsECCO '18 Vienna
Year: 2018
Authors:

C. Selinger1, G.C. Parkes2*, M. Adamson3, A. Bassi4, F. Donovan5, A. Fraser6, B. George7, L. Grey8, V. Hall9, J. Lindi10, H. Ludlow11, I. Parisi12, P. Patel13, R. Pollock14, S. Salunke15, J. Saunders16, G. Scott17, M. Smith18, T. Raine19

1Leeds Teaching Hospitals, Leeds, UK, 2Royal London Hospital, Barts Health, London, UK, 3Salisbury NHS Foundation Trust, Salisbury, UK, 4St Helens and Knowsley Foundation Trust, St Helens, UK, 5Kingston Hospital NHS Foundation Trust, Kingston upon Thames, UK, 6Bristol Royal Infirmary, Bristol, UK, 7Torbay and South Devon NHS Trust, Torbay, UK, 8Wirral University Teaching Hospital, Birkenhead, UK, 9Royal Bolton Hospital, Bolton, UK, 10North Manchester General Hospital, Manchester, UK, 11University Hospital Llandough, Cardiff, UK, 12University College London Hospitals, London, UK, 13Epsom and St Helier University Hospitals NHS Trust, Epsom, UK, 14St George's University Hospitals NHS Foundation Trust, London, UK, 15Forth Valley Royal Hospital, Larbert, UK, 16Royal United Hospitals Bath NHS Foundation Trust, Bath, UK, 17East Kent Hospitals University NHS Foundation Trust, Margate, UK, 18Brighton and Sussex University Hospitals NHS Trust, Brighton, UK, 19Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Orlando1*, F.S. Macaluso1, W. Fries2, A.C. Privitera3, M. Cappello4, S. Siringo5, G. Inserra6, A. Magnano7, R. Di Mitri8, N. Belluardo9, G. Scarpulla10, G. Magrì11, N. Trovatello12, A. Carroccio13, S. Genova14, C. Bertolami15, R. Vassallo16, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo, Italy, 2Inflammatory Bowel Disease Unit, A.O.U. Policlinico "G. Martino”, Messina, Italy, 3IBD Unit, A.O. "Cannizzaro”, Catania, Italy, 4Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy, 5Gastroenterology Unit, A.R.N.A.S. “Garibaldi”, Catania, Italy, 6Internal Medicine Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy, 7Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy, 8Gastroenterology and Endoscopy Unit, A.R.N.A.S. “Civico Di Cristina Benfratelli”, Palermo, Italy, 9Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy, 10Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy, 11Gastroenterology Unit, A.O. “Santa Marta e S. Venera”, Acireale, Italy, 12Surgery Unit, A.O. “Umberto I”, Siracusa, Italy, 13Internal Medicine Unit, A.O. “Giovanni Paolo II”, Sciacca, Italy, 14Gastroenterology and Endoscopy Unit, A.O. “S. Antonio Abate”, Trapani, Italy, 15Gastroenterology Unit, A.O.O.R. “Papardo Piemonte”, Messina, Italy, Messina, Italy, 16Gastroenterology and Endoscopy Unit, A.O. “Buccheri La Ferla Fatebenefratelli”, Palermo, Italy

P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort seriesECCO '18 Vienna
Year: 2018
Authors:

M.E. Stellingwerf1*, S. Sahami1, D.C. Winter2, H.E. Mulcahy2, G. Doherty2, G. Cullen2, S. Martin2, G.R. D'Haens3, W.A. Bemelman1, C.J. Buskens1

1Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands, 2St Vincent's University Hospital, Department of Colorectal Disease, Dublin, Ireland, 3Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands

P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatmentsECCO '18 Vienna
Year: 2018
Authors:

C. Hommel1*, X. Roblin2,3, L. Brichet2,3, B. Bihin4, S. Pillet3,5, J.-F. Rahier1

1CHU UCL Namur, Catholic University of Louvain, Gastroenterology and Hepatology, Yvoir, Belgium, 2University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 3Faculty of Medicine of Saint-Etienne, University of Lyon, EA-3064, Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Lyon, France, 4CHU UCL Namur, Scientific Support Unit, Yvoir, Belgium, 5University of Saint Etienne, Laboratory of Infectious Agents and Hygiene, Saint Etienne, France

P580: Vitamin D substitution dose in IBD patients: Higher than recommended?ECCO '18 Vienna
Year: 2018
Authors:

V. Kojecky1*, J. Matous2, Z. Zadorova3, P. Kohout4

1Bata Regional Hospital, Internal Clinic, Zlin, Czech Republic, 2Third Faculty of Medicine, Charles University in Prague, 2nd Department of Internal Medicine, Prague, Czech Republic, 3Third Faculty of Medicine, Charles University in Prague, 2nd Department of Internal Medicine, Prague, Czech Republic, 4Thomayer Hospital, 2nd Department of Internal Medicine, Prague, Czech Republic

P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohortECCO '18 Vienna
Year: 2018
Authors:

V. Pittet1*, N. Aslan2, N. Fournier1, A. Decollogny1, A. Schoepfer2, F. Seibold3, P.-Y. Rodondi4

1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2Lausanne University Hospital, Department of Gastroenterology and Hepatology, Lausanne, Switzerland, 3Lindenhof Spital, Division of Gastroenterology, Bern, Switzerland, 4Institute of Social and Preventive Medicine, Centre for Integrative and Complementary Medicines, Lausanne, Switzerland

P582: Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohortECCO '18 Vienna
Year: 2018
Authors:

J. Doherty*, M. Buckley, G. Cullen, G. Horgan, H. Mulcahy, G. Doherty, J. Sheridan

St Vincents University Hospital and School of Medicine, University College Dublin, Centre for Colorectal Disease, Dublin 4, Ireland

P583: Efficacy of vedolizumab (VDZ) by disease extension in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

P. Michetti1*, F. Braegger2, C. Kempf2, M. Allez3

1Gastro-entérologie La Source-Beaulieu and Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Crohn and Colitis Center, Lausanne, Switzerland, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Hôpital Saint-Louis, APHP, INSERM UMRS 1160, Université Denis Diderot, Gastroenterology and Hepatology, Paris, France

P584: Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnetECCO '18 Vienna
Year: 2018
Authors:

M. Aardoom1*, P. Kemos2, F. Ruemmele3, N. Croft2, L. de Ridder1, on behalf of the PIBD SETQuality consortium and PIBDnet

1Erasmus MC, Sophia Children's Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands, 2Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, Paediatric Gastroenterology, London, UK, 3Université Paris Descartes, Sorbonne Paris Cité, APHP, Hopital Necker Enfants Malades, Department of Paediatric Gastroenterology, Paris, France

P585: Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015ECCO '18 Vienna
Year: 2018
Authors:

S.Y. Shin1*, J. Lee2, J.J. Park1, J.H. Cheon3, T.I. Kim3, H. Park1, W.H. Kim3, A.S. Shin2

1Gangnam Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea, 2Seoul National University College of Medicine, Preventive Medicine, Seoul, South Korea, 3Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea

P586: Tofacitinib for the induction and maintenance of medically resistant ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

R. Weisshof*, M. Aharoni Golan, D.T. Rubin

University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, USA

P587: Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case seriesECCO '18 Vienna
Year: 2018
Authors:

V. Biemans1,2*, C. van der Woude3, G. Dijkstra4, A. van der Meulen - de Jong5, B. Oldenburg6, N. de Boer7, C. Ponsioen8, A. de Vries3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

1Radboudumc, Nijmegen, The Netherlands, 2Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 3Erasmus Medical Center, Rotterdam, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands, 5Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 6University Medical Centre Utrecht, Utrecht, The Netherlands, 7VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, 8Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands

P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determinationECCO '18 Vienna
Year: 2018
Authors:

M. Daperno*, C. Guiotto, A. Italia, A. Lavagna, A. Negri, E. Ercole, M. Cosimato, C. Rigazio, R. Rocca

Mauriziano Hospital, Gastroenterology Unit, Torino, Italy

P589: Adherence to medical treatment in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Jardak1*, L. Hamzaoui1,2,3, K. Agar2, M. Medhioub2, A. Khsiba2, M.M. Azouz2

1Nabeul-Tunisia, Department of Gastroenterology Nabeul-Tunisia, Nabeul, Tunisia, 2Nabeul-Tunisia, Nabeul-Tunisia, Nabeul, Tunisia, 3Mohamed Taher Maamouri Hospital, Department of Gastroenterology, Nabeul, Tunisia

P590: Laparoscopy in Crohn’s disease: Learning curve and current practiceECCO '18 Vienna
Year: 2018
Authors:

D. Mege1,2*, F. Michelassi1

1New York Presbyterian Hospital, New York, USA, 2Aix-Marseille University, Marseille, France

P591: Gastroenterologist performed point-of-care gastrointestinal ultrasound improves patient understanding of disease activity, symptomatology, management decisions and clinical outcomesECCO '18 Vienna
Year: 2018
Authors:

A. Friedman1*, A. Asthana1,2, S. Knowles3, A. Robbins4, P. Gibson1

1The Alfred Centre, Department of Gastroenterology, Monash University, Melbourne, Australia, 2The Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, 3Swinburne University, Psychological Sciences and Statistics, Hawthorn, Australia, 4AbbVie Pty Ltd., Immunology (Medical), Sydney, Australia

P592: Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experienceECCO '18 Vienna
Year: 2018
Authors:

M. Vinayaga-Pavan*, T. Kumagai, I. Parisi, J. Barragry, R. Sundramoorthi, L. Whitley, H. Parker, R. Kettle, N. McCabrey, E. Steward, S. McCartney, S. Bloom, R. Vega, S. Mehta, F. Rahman

University College London Hospital, Department of Gastroenterology, London, UK

P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre studyECCO '18 Vienna
Year: 2018
Authors:

C. Briot1*, P. Faure2, A.L. Parmentier1, C. Gay1, C. Trang3, M. Nachury4, S. Viennot5, R. Altwegg6, P. Bulois7, L. Thomassin8, M. Serrero9, P. Ah Soune10, C. Gilletta11, L. Plastaras12, M. Simon13, X. Dray14, L. Caillo15, E. Del Tedeco16, V. Abitbol17, C. Zallot18, T. Degand19, V. Rossi20, G. Bonnaud21, D. Colin22, B. Morel23, J.B. Danset24, B. Winkfield25, J. Filippi26, A. Amiot27, A. Attar28, A. Bourreille29, J.C. Grimaud9, A. Blain30, L. Peyrin Biroulet18, L. Vuitton1

1University Hospital Center Jean Minjoz, Gastroenterology, Besancon, France, 2Private Clinic Pasteur, Gastroenterology, Toulouse, France, 3University Hospital Center, Gastroenterology, Nantes, France, 4University Hospital Center, Gastroenterology, Lille, France, 5University Hospital Center, Gastroenterology, Caen, France, 6Private Practise, Gastroenterology, Montpellier, France, 7Private Clinic La Louviere, Gastroenterology, Lille, France, 8University Hospital Center, Gastroenterology, Rouen, France, 9Aphm North Hospital, Gastroenterology, Marseille, France, 10Private Practice, Gastroenterology, Toulon, France, 11University Hospital Center Rangueil, Gastroenterology, Toulouse, France, 12Hospital Louis Pasteur, Gastroenterology, Colmar, France, 13Hospital Saint Louis APHP, Gastroenterology, Paris, France, 14Hospital Saint Antoine APHP, Gastroenterology, Paris, France, 15University Hospital Center Caremeau, Gastroenterology, Nimes, France, 16University Hospital Center, Gastroenterology, Saint Etienne, France, 17University Hospital Center Cochin APHP, Gastroenterology, Paris, France, 18University Hospital Center Brabois, Gastroenterology, Nancy, France, 19University Hospital Center Le Bocage, Gastroenterology, Dijon, France, 20Hospital Haut Anjou, Gastroenterology, Chateau Gontier, France, 21Private Clinic Des cèdres, Gastroenterology, Cornebarrieu, France, 22Private Practice, Gastroenterology, Belfort, France, 23Private Hospital, Gastroenterology, Saint Priest en Jarez, France, 24European Hospital Georges Pompidou APHP, Gastroenterology, Paris, France, 25Hospital HNFC, Gastroenterology, Trevenans, France, 26University Hospital Center Larchet, Gastroenterology, Nice, France, 27University Hospital Henri Mondor APHP, Gastroenterology, Créteil, France, 28Private Practice, Gastroenterology, Paris, France, 29University Hospital Center Hôtel Dieu, Gastroenterology, Nantes, France, 30Institut Mutualiste Montsouris, Gastroenterology, Paris, France

P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)ECCO '18 Vienna
Year: 2018
Authors:

J. Panés1*, D. García-Olmo2, A. Parfionovas3, C. Agboton4, J.M. Khalid5

1Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Gastroenterology Department, Barcelona, Spain, 2Faculty of Medicine, Autonomous University of Madrid, Department of Surgery, Madrid, Spain, 3Takeda Pharmaceuticals International Co., Cambridge, USA, 4Takeda Pharmaceuticals International AG, Zurich, Switzerland, 5Takeda Development Centre, London, UK

P595: Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREGECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, D. Bergemalm1*, L. Vigren2, L. Nilsson3, I. Visuri1, H. Hjortswang4, R. Udumyan5, S. Almer6, M. Seddighzadeh7, E. Hertervig8, P. Karlén3, H. Strid9, J. Halfvarson1, The GO-SWIBREG study group

1Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 2Hospital of Trelleborg, Department of Medicine, Division of Gastroenterology, Trelleborg, Sweden, 3Danderyd Hospital, Department of Internal Medicine, Stockholm, Sweden, 4Linköping University, Department of Gastroenterology and Department of Clinical and Experimental Medicine, Linköping, Sweden, 5Örebro University, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro, Sweden, 6Karolinska Institute, Department of Medicine, Gastrocentrum, Stockholm, Sweden, 7Merck Sharp and Dohme, Sweden, Stockholm, Sweden, 8Skåne University Hospital, Department of Gastroenterology, Lund, Sweden, 9Södra Älvsborgs Hospital, Department of Internal Medicine, Borås, Sweden